FDA regulatory context, and consumer verification steps for men evaluating doctor-prescribed ED medication access online in ...

A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.

The typical buprenorphine dosage for opioid use disorder is 2 mg to 8 mg. Buprenorphine comes as a sublingual tablet and is usually taken once per day. It’s important to take the buprenorphine dosage ...

Buprenorphine sublingual tablet is prescribed to treat opioid use disorder in two phases: an induction phase to manage initial withdrawal symptoms and a maintenance phase for long-term treatment. You ...

Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) ...

According to the Company, the product is not temperature sensitive and remains stable under extreme conditions (from -20°C/-4°F to 60°C/140°F). The Food and Drug Administration (FDA) has granted Fast ...

The US Food and Drug Administration (FDA) has approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film for the treatment of opioid dependence, which may increase ...

March 22, 2026 – National Institutes of Health (NIH) released the following: ...

Cooper EMS paramedics can now administer extended-release buprenorphine in the field, giving overdose patients longer ...

India, March 19 -- Weekly buprenorphine injections demonstrate a superior safety profile compared to daily oral dosing and serve as a highly effective treatment for Opioid Use Disorder (OUD) in ...